Blueprint Medicines (BPMC) Priced

Preclinical biotech developing kinase inhibitors for cancer and genetic diseases.

Health Care - Biotechnology

IPO Performance
Latest Trade $33.30 0.00 (0.0%)
First Day Return 4.8%
Return from IPO 85.0%
 
Blueprint Medicines IPO News more
  • .
IPO Data
IPO File Date 03/23/2015
Offer Price $18.00
Price Range $15.00 - $17.00
Offer Shares (mm) 8.1
Deal Size ($mm) 147
 
IPO Data
IPO Date 04/29/2015
Offer Price $18.00
Price Range $15.00 - $17.00
Offer Shares (mm) 8.1
Deal Size ($mm) $147
 
Underwriters
more
Business Overview
Preclinical biotech developing kinase inhibitors for cancer and genetic diseases.
Preclinical biotech developing kinase inhibitors for cancer and genetic diseases.
more
Company Data
Headquarters Cambridge, MA
Founded 2008
Employees 60
Website www.blueprintmedicines.com
 

Performance vs. IPO Index (IPOUSA)